Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia

Table 3 Multivariate analysis of MRSA versus MSSA: duration of MV, inpatient LOS, ICU LOS, and total cost

Dependent variables	MRSA estimate (95% CI)	P value	Model r²
Total MV (days)	4.4 (0.6 to 8.2)	0.03	0.16
VAP MV (days)	4.5 (1.0 to 8.1)	0.01	0.10
Total inpatient LOS (days)	3.8 (-0.5 to +8.0)	0.08	0.26
VAP inpatient LOS (days)	3.7 (-0.5 to +8.0)	0.08	0.06
Total ICU (days)^a	5.3 (1.0 to 9.7)	0.02	0.13
VAP ICU (days)^a	4.4 (0.4 to 8.4)	0.03	0.10
Total cost (US$)	7731 (-8393 to +23,856)	0.35	0.28

A total of 154 patients were included in this analysis. ^aAnalysis for ICU days was conducted on patients (n = 95) from hospitals that collect ICU stay data. CI, confidence interval; ICU, intensive care unit; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MV, mechanical ventilation; VAP, ventilator-associated pneumonia.

ISSN: 1364-8535